Results 91 to 100 of about 3,775 (204)

Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.

, 2012
Fidaxomicin has recently been approved for the treatment of Clostridium difficile infection (CDI). As part of phase III studies, plasma and fecal samples were analyzed for concentrations of fidaxomicin and its metabolite, OP-1118.
Sears, P, Louie, TJ, Crook, DW, Miller, MA, Weiss, K   +4 more
core   +1 more source

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?

, 2012
Until recently, treatment of Clostridium difficile infection (CDI) was mainly limited to oral metronidazole and vancomycin, neither of which is optimal. Up to 25% of patients with CDI experience recurrence of infection within 30 days following treatment ...
Cornely, O.A.
core   +1 more source

Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection

, 2011
A 10-day course of oral fidaxomicin (200 mg twice a day [b.i.d.]), a potent new macrocyclic drug, was compared to vancomycin (125 mg four times a day [q.i.d.]) in 1,164 adults (1,105 in the modified intent-to-treat [mITT] population) with ...
Ellie J. C. Goldstein, Farah Babakhani, Pamela Sears, Susan P. Sambol, Dale N. Gerding, Diane M. Citron   +5 more
core   +1 more source

Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-κB Activity

, 2018
Clostridium difficile causes diarrhea and colitis by releasing toxin A and toxin B. In the human colon, both toxins cause intestinal inflammation and stimulate tumor necrosis factor alpha (TNF-α) expression via the activation of NF-κB.
Diana Hoang-Ngoc Tran, Jiani Wang, Charalabos Pothoulakis, Xinhua Chen, Christina Ortiz, Caroline C. Mussatto, Ciaran P. Kelly, Elaine C. Lee, Hon Wai Koon   +8 more
core   +1 more source

In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin

, 2013
Objectives: Current treatments for Clostridium difficile infection include vancomycin, metronidazole, and fidaxomicin. LFF571 is an experimental agent undergoing evaluation in humans for the treatment of moderate C. difficile infection.
Leeds, Jennifer, Sachdeva, Meena, Barnes, Whitney, Ruzin, Alexey, Mullin, Steve   +4 more
core   +1 more source

Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

Infection and Drug Resistance, 2017
Amanda R D’Ostroph,1 Tsz-Yin So2 1UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, 2Department of Pharmacy, Moses H Cone Memorial Hospital, Greensboro, NC, USA Abstract: The incidence of Clostridium ...
D'Ostroph AR, So TY
doaj  

142 Diagnostic Stewardship of Urine Testing Through Clinical Decision Support: An Interrupted Time Series Analysis

Antimicrobial Stewardship & Healthcare Epidemiology
Background: Clostridioides difficile infection (CDI) remains one of the most common healthcare-associated infections and contributes significantly to morbidity, mortality, and healthcare costs.
Marianna Almpani, Daniel O’Connor, Jennifer Do, Jessica Lomanno, Theodore (Ted) Rader   +4 more
doaj   +1 more source

UEG Week 2025 Poster Presentations

United European Gastroenterology Journal, Volume 13, Issue S8, Page S803-S1476, October 2025.
wiley   +1 more source

Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan

Antibiotics
Background/Objectives: Clostridioides difficile infection (CDI) poses a significant healthcare challenge, with recurrence rates reaching 30%, leading to substantial morbidity and costs.
Jun Hirai, Nobuaki Mori, Yuki Hanai, Nobuhiro Asai, Mao Hagihara, Hiroshige Mikamo   +5 more
doaj   +1 more source

Fidaxomicin Inhibits Clostridium difficile Toxin A-Mediated Enteritis in the Mouse Ileum

, 2014
Clostridium difficile infection (CDI) is a common, debilitating infection with high morbidity and mortality. C. difficile causes diarrhea and intestinal inflammation by releasing two toxins, toxin A and toxin B.
Chen, Xinhua, Pothoulakis, Charalabos, Hing, Tressia C, Ho, Samantha, Koon, Wai, Cheng, Michelle, Ichikawa, Yoshi, Kelly, Ciarán P   +7 more
core   +1 more source